Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach

Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach

Anti-angiogenic agents are biological drugs used for treatment of retinal neovascular degenerative diseases. In this study, we aimed at in-silico analysis of interaction of vascular endothelial growth factor A (VEGFA), the main mediator of angiogenesis, with binding domains of anti-angiogenic agents...

Full description

Bibliographic Details
Main Authors:	Chiara Bianca Maria Platania, Luisa eDi Paola, Gian Marco eLeggio, Giovanni Luca eRomano, Filippo eDrago, Salvatore eSalomone, Claudio eBucolo
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2015-10-01
Series:	Frontiers in Pharmacology
Subjects:	Diabetic Retinopathy molecular dynamics bevacizumab Aflibercept Ranibizumab
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fphar.2015.00248/full

Similar Items

Erratum: Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach
by: Science eProduction Office
Published: (2016-06-01)

Review of effects of anti-VEGF treatment on refractive error
by: Mintz-Hittner HA, et al.
Published: (2016-06-01)

Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis
by: Kiss S, et al.
Published: (2018-08-01)

ANGIOGENESIS IN PROLIFERATIVE DIABETIC RETINOPATHY: RERSPECTIVES OF ANTI-VEGF THERAPY (REVIEW OF LITERATURE)
by: V. I. Konenkov, et al.
Published: (2015-12-01)

pH of anti-VEGF agents in the human vitreous: low impact of very different formulations
by: Bianka Sobolewska, et al.
Published: (2017-06-01)

Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients
by: J. M. Ruiz-Moreno, et al.
Published: (2020-09-01)

Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization
by: Tariq Al-Debasi, et al.
Published: (2017-04-01)

Incidence of endophthalmitis after intravitreal application of anti VEGF therapy at the University Clinical Center in Tuzla, Bosnia and Herzegovina
by: Svjetlana Terzić, et al.
Published: (2015-08-01)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
by: Pessoa B, et al.
Published: (2021-01-01)

Immediate sequential bilateral intravitreal injections: an Indian perspective
by: Tripathy K
Published: (2017-04-01)

Efficacy of intravitreal injection of Aflibercept vs Ranibizumab in the treatment of diabetic retinopathy
by: Chang Huang, et al.
Published: (2021-05-01)

Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature
by: Irini Chatziralli, et al.
Published: (2021-07-01)

Managing Diabetic Macular Edema in Clinical Practice: Systematic Review and Meta-Analysis of Current Strategies and Treatment Options
by: Veritti D, et al.
Published: (2021-01-01)

Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
by: Thomas BJ, et al.
Published: (2016-08-01)

Potential drug mechanism(s) targeting the contractile status of hepatic stellate cells
by: Claudio eBucolo, et al.
Published: (2012-10-01)

Ocular drug delivery: A clue from nanotechnology
by: Claudio eBucolo, et al.
Published: (2012-10-01)

Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal study
by: Benjamin Chi-Lan Yang, et al.
Published: (2019-01-01)

Pharmacokinetic Simulations of Intravitreal Biologicals: Aspects of Drug Delivery to the Posterior and Anterior Segments
by: Anna-Kaisa Rimpelä, et al.
Published: (2018-12-01)

Comparison of the efficacy of aflibercept and ranibizumab after a 3-month loading dose in patients with diabetic macular edema
by: Murat Çakmaklıoğulları, et al.
Published: (2021-03-01)

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
by: Alsaedi NG, et al.
Published: (2021-07-01)

Management of Macular Edema Secondary to Branch Retinal Vein Occlusion in an Eye with Prior Vitrectomy and Lensectomy
by: Pankaj Malhotra, et al.
Published: (2014-10-01)

Should we consider pars plana vitrectomy in the primary treatment of diabetic macular edema?
by: Lihteh Wu, et al.
Published: (2017-01-01)

Should We Consider Pars Plana Vitrectomy in the Primary Treatment of Diabetic Macular Edema?
by: Lihteh Wu, et al.
Published: (2017-04-01)

Anti-angiogenic therapy for ovarian cancer
by: Yolanda García García, et al.
Published: (2020-08-01)

Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity
by: Lin CJ, et al.
Published: (2016-07-01)

Evaluation of the Safety of Bilateral Same-Day Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents: Experience of a Large Korean Retina Center
by: Jang K, et al.
Published: (2020-10-01)

The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy
by: Yue Zhao, et al.
Published: (2018-08-01)

Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies
by: Anna A. Plyukhova, et al.
Published: (2020-05-01)

Vascular endothelial growth factor inhibition and proliferative diabetic retinopathy, a changing treatment paradigm?
by: Lihteh Wu, et al.
Published: (2019-01-01)

Meta-analysis of comparison of IVB and IVR used for retinopathy of prematurity
by: Rong-Xia Cao, et al.
Published: (2021-03-01)

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2)
by: Jumper JM, et al.
Published: (2018-04-01)

Two-Year Outcome of Aflibercept for the Treatment of Choroidal Neovascularization in Punctate Inner Choroidopathy
by: Luis Arrevola, et al.
Published: (2019-01-01)

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
by: Khanani AM, et al.
Published: (2019-02-01)

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
by: Kaiser SM, et al.
Published: (2021-09-01)

Comparative study between ranibizumab and aflibercept in the management of macular edema caused by diabetes mellitus in age group more than 40 years
by: Abd El-Magid M Tag El-Din
Published: (2019-01-01)

Experimental histopathological study on retinal and renal cellular response to intravitreous antiangiogenic drugs
by: João Borges Fortes Filho, et al.
Published: (2014-06-01)

Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years’ Real-World Clinical Outcomes
by: Horner F, et al.
Published: (2021-04-01)

Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
by: Maria Waizel, et al.
Published: (2017-05-01)

Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients
by: Adrian Skelly, et al.
Published: (2019-08-01)

Intravitreal aflibercept for choroidal neovascularization secondary to angioid streaks in a non-responder to intravitreal ranibizumab
by: Makri OE, et al.
Published: (2018-09-01)

Cannot write session to /tmp/vufind_sessions/sess_f2mpc79179q4egql5jf8dkjvq1